Correlation Salivary Cortisol and Free Serum Cortisol to Total Serum Cortisol in MICU Septic Shock

This study has been completed.
Information provided by (Responsible Party):
Rosa Estrada Y Martin, The University of Texas Health Science Center, Houston Identifier:
First received: August 30, 2007
Last updated: December 2, 2014
Last verified: December 2014

The purpose of the study is:

  • to correlate salivary cortisol to free serum cortisol (as salivary cortisol is considered to be almost complete free cortisol) and,
  • to correlate free serum cortisol to total serum cortisol levels

Both in patients with septic shock (severe sepsis requiring vasopressors).

We believe that:

  • total serum cortisol does not correlate with free serum cortisol in patient with septic shock and,
  • that salivary cortisol correlates with free serum cortisol and can be used to determine the level of free serum cortisol.

Septic Shock

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Correlation Between Salivary Cortisol and Free Serum Cortisol Compared to Total Serum Cortisol in MICU Patients With Septic Shock

Resource links provided by NLM:

Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Salivary cortisol [ Time Frame: one year ] [ Designated as safety issue: No ]
    salivary cortisol in mg/dL

Enrollment: 60
Study Start Date: February 2007
Study Completion Date: October 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Free serum cortisol is considered the active hormone.

In patients with septic shock only the total serum cortisol level is available, however, the free cortisol level can be normal despite a low total cortisol level due to changes in the serum protein.

The hormone can be replaced improperly in these patients and contribute to poor outcome in septic shock.

We are studying adult MICU patients with septic shock who are not receiving corticosteroid replacement.

This study does not include any intervention.

In-hospital or 28-day mortality are registered in all the patients.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

MICU patients with septic shock


Inclusion Criteria:

  • Adult patients with septic shock

Exclusion Criteria:

  • Corticosteroid replacement
  • Blood in mouth
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00523198

United States, Texas
The University of Texas- Health Science Center at Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Principal Investigator: Rosa M Estrada-Y-Martin, MD The University of Texas-Health Science Center at Houston / Division of Pulmonary, Sleep and Critical Care Medicine
  More Information

No publications provided by The University of Texas Health Science Center, Houston

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Rosa Estrada Y Martin, Associate Professor, The University of Texas Health Science Center, Houston Identifier: NCT00523198     History of Changes
Other Study ID Numbers: HSC-MS-06-413, M01-RR 02558 (GCRC)
Study First Received: August 30, 2007
Last Updated: December 2, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by The University of Texas Health Science Center, Houston:

Additional relevant MeSH terms:
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Cortisol succinate
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Anti-Inflammatory Agents
Dermatologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on October 08, 2015